At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02171 CARSGEN-B
Market Closed 06-05 16:09:12
16.320
-0.280
-1.69%
High17.440
Low16.320
Vol5.55M
Open16.700
D1 Closing16.600
Amplitude6.75%
Mkt Cap9.71B
Tradable Cap9.71B
Total Shares595.00M
T/O92.84M
T/O Rate0.93%
Tradable Shares595.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CARsgen issues 23.73 million new shares in May; total share count rises 4.16 %, public float intact
Movement Alert｜CARsgen Therapeutics-B Declines 5.14% in Regular Trading, Discounted Placement Dilution and Biotech Sector Weakness Continue to Pressure Shares
Movement Alert｜CARsgen Therapeutics-B Declines 5.02% in Regular Trading, Discounted Placement Dilution and Institutional Selling Continue to Pressure Shares
Long-Term Follow-up Results of CARsgen's Satri-Cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 Asco Annual Meeting
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.